Expert review of neurotherapeutics · 2026
Corticosteroids in withdrawal therapy following medication-overuse headache: a systematic review.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
da Silva Evelliny Gomes, de Sousa Jonata Ribeiro, Moraes Monteiro Barbosa Barros Manuella, de Oliveira Felipe Araújo Andrade, Rocha-Filho Pedro Augusto Sampaio
Аннотация
INTRODUCTION: Medication-overuse headache (MOH) affects 1-2% of the population and imposes substantial burden. Corticosteroids are often used as bridge therapy during withdrawal, although their effectiveness remains uncertain. This study aims to evaluate the effectiveness of corticosteroids as a withdrawal strategy in MOH.
METHODS: A systematic review with meta-analysis was conducted in accordance with PRISMA guidelines. The protocol was registered in PROSPERO (ID: 1161824). Searches were performed in PubMed, MEDLINE, EMBASE, the Cochrane Library, Web of Science, SciELO, and LILACS through June 2025. Randomized, placebo-controlled trials assessing corticosteroids during withdrawal therapy in adults with MOH were included. Random-effects meta-analyses were performed when feasible using RevMan 7.2.0.
RESULTS: Of 4,483 records identified, four trials comprising 250 participants met eligibility criteria. Two studies presented high risk of bias, two raised some concerns. Considerable heterogeneity in design, dosing regimens, follow-up duration, and outcome definitions limited comparability and precluded a unified pooled analysis. Across studies, results consistently failed to show benefit. Meta-analytic findings demonstrated no advantage of corticosteroids over placebo regarding early withdrawal headache, withdrawal symptoms or reversal of medication overuse.
CONCLUSION: The available evidence does not support corticosteroids as effective withdrawal therapy for MOH.
METHODS: A systematic review with meta-analysis was conducted in accordance with PRISMA guidelines. The protocol was registered in PROSPERO (ID: 1161824). Searches were performed in PubMed, MEDLINE, EMBASE, the Cochrane Library, Web of Science, SciELO, and LILACS through June 2025. Randomized, placebo-controlled trials assessing corticosteroids during withdrawal therapy in adults with MOH were included. Random-effects meta-analyses were performed when feasible using RevMan 7.2.0.
RESULTS: Of 4,483 records identified, four trials comprising 250 participants met eligibility criteria. Two studies presented high risk of bias, two raised some concerns. Considerable heterogeneity in design, dosing regimens, follow-up duration, and outcome definitions limited comparability and precluded a unified pooled analysis. Across studies, results consistently failed to show benefit. Meta-analytic findings demonstrated no advantage of corticosteroids over placebo regarding early withdrawal headache, withdrawal symptoms or reversal of medication overuse.
CONCLUSION: The available evidence does not support corticosteroids as effective withdrawal therapy for MOH.